Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy

BACKGROUND: The tumor-selective human adenovirus Delta24-RGD is currently under investigation in phase II clinical trials for patients with recurrent glioblastoma (GBM). To improve treatments for patients with GBM, we explored the potential of combining Delta24-RGD with antibodies targeting immune c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Belcaid, Zineb, Berrevoets, Cor, Choi, John, van Beelen, Edward, Stavrakaki, Eftychia, Pierson, Tessa, Kloezeman, Jenneke, Routkevitch, Denis, van der Kaaij, Mariëlle, van der Ploeg, Alicia, Mathios, Dimitrios, Sleijfer, Stefan, Dirven, Clemens, Lim, Michael, Debets, Reno, Lamfers, Martine L M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212906/
https://ncbi.nlm.nih.gov/pubmed/32642679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados